ZENITH EPIGENETICS LTD.
25Patents
24Active
25Granted
48Portfolio score
Filing activity: Nov 20, 2013 → Jul 28, 2020
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9271978B2 | Heterocyclic compounds as bromodomain inhibitors | Emerging Cross-Sectional Technologies | 29 | Active |
| US9278940B2 | Cyclic amines as bromodomain inhibitors | Emerging Cross-Sectional Technologies | 26 | Active |
| US9765039B2 | Biaryl derivatives as bromodomain inhibitors | Emerging Cross-Sectional Technologies | 24 | Active |
| US9662311B2 | Substituted bicyclic compounds as bromodomain inhibitors | Emerging Cross-Sectional Technologies | 23 | Active |
| US9861637B2 | Heterocyclic compounds as bromodomain inhibitors | Emerging Cross-Sectional Technologies | 21 | Active |
| US9073878B2 | Cyclic amines as bromodomain inhibitors | Emerging Cross-Sectional Technologies | 21 | Active |
| US9636328B2 | Substituted bicyclic compounds as bromodomain inhibitors | Emerging Cross-Sectional Technologies | 20 | Active |
| US9663520B2 | Bicyclic bromodomain inhibitors | Emerging Cross-Sectional Technologies | 16 | Active |
| US9598367B2 | Heterocyclic compounds as bromodomain inhibitors | Emerging Cross-Sectional Technologies | 16 | Active |
| US9855271B2 | Quinazolinones as bromodomain inhibitors | Chemistry; Metallurgy | 13 | Active |
| US10363257B2 | Bicyclic bromodomain inhibitors | Emerging Cross-Sectional Technologies | 8 | Active |
| US10292968B2 | Substituted heterocycles as bromodomain inhibitors | Emerging Cross-Sectional Technologies | 6 | Active |
| US10010556B2 | Bicyclic bromodomain inhibitors | Emerging Cross-Sectional Technologies | 3 | Active |
| US10166215B2 | Substituted bicyclic compounds as bromodomain inhibitors | Emerging Cross-Sectional Technologies | 1 | Active |
| US10226451B2 | Substituted bicyclic compounds as bromodomain inhibitors | Emerging Cross-Sectional Technologies | 1 | Active |
| US10500209B2 | Quinazolinones as bromodomain inhibitors | Chemistry; Metallurgy | 0 | Active |
| US11446306B2 | Bicyclic bromodomain inhibitors | Emerging Cross-Sectional Technologies | 0 | Active |
| US10710992B2 | Substituted pyridinones as bromodomain inhibitors | Chemistry; Metallurgy | 0 | Active |
| US10231953B2 | Inhibitors of bromodomains | Emerging Cross-Sectional Technologies | 0 | Active |
| US12145932B2 | Method of manufacturing a solid form of a BET bromodomain inhibitor | Chemistry; Metallurgy | 0 | Active |
| US9999616B2 | Substituted bicyclic compounds as bromodomain inhibitors | General | 0 | Revoked |
| US10179125B2 | Substituted pyridines as bromodomain inhibitors | Emerging Cross-Sectional Technologies | 0 | Active |
| US11607405B2 | Combination therapy for the treatment of triple-negative breast cancer | Human Necessities | 0 | Active |
| US11026926B2 | Substituted bicyclic compounds as bromodomain inhibitors | Emerging Cross-Sectional Technologies | 0 | Active |
| US10772892B2 | Bicyclic bromodomain inhibitors | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.